National Acalabrutinib Observational Study

N/AActive Not RecruitingNCT05437250

AstraZeneca350 enrolled

Overview

The efficacy and safety of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL) have been well established through 3 phase III clinical trials (ELEVATE TN, ASCEND, ELEVATE R/R) that led to European Medicines Agency approval in November 2020. The aim of this French longitudinal, non-interventional/observational, multicenter study is to describe the efficacy and safety of acalabrutinib treatment for CLL patients in real life. The primary objective is then to estimate the time to discontinuation of acalabrutinib therapy and the reasons for discontinuation, overall and by treatment line. The secondary objectives are to describe the baseline clinical and demographic characteristics of patients with CLL treated with acalabrutinib, to assess the efficacy of acalabrutinib through progression-free survival, overall survival, time to next treatment or death, describe acalabrutinib treatment patterns in CLL patients and reasons, identify key determinants of acalabrutinib discontinuation in CLL patients, estimate healthcare resource utilization. The overall response rate will be estimated as an exploratory objective. Patients included in this study will be CLL patients treated with acalabrutinib at the discretion of their physician between January 1, 2021 and December 31, 2022, who have been informed of the study and do not object to electronic processing of their data for research purposes (or do not object during their lifetime in the event of the patient's death prior to study initiation). Secondary data will be extracted from the hospital's patient records once a year. The protocol calls for the recruitment of 350 patients at 70 centres with a 3-year follow-up. Interim analyses will be performed annually until the end of the study.

Study Type

OBSERVATIONAL

Enrollment

350

Conditions

Chronic Lymphocytic Leukemia

Interventions

Non interventional studyDRUG

CLL patients initiated with acalabrutinib at their physician's discretion between January 1, 2021 and December 31, 2022 . Secondary data collection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patients aged ≥ 18 years old, * CLL patients initiated with acalabrutinib at their physician's discretion between January 1st 2021 and December 31st 2022, * Patients alive at study initiation and who have been informed verbally and/or in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control (certified by physician); or patient who died before study initiation and who did not object to data collection for research purpose(s) during his or her lifetime. Exclusion Criteria: * Patients participating in a clinical trial with an investigational drug within 30 days prior to acalabrutinib initiation, * Patients who initiated acalabrutinib treatment before January 1st 2021.

Locations (61)

Research Site

Aix-en-Provence, France

Research Site

Amiens, France

Research Site

Angers, France

Research Site

Ars-Laquenexy, France

Research Site

Avignon, France

Research Site

Besançon, France

Outcomes

Primary Outcomes

Time to Discontinuation

Time between first day of acalabrutinib and the day that acalabrutinib is stopped

Time frame: Up to 3 years from the start of acalabrutinib

Secondary Outcomes

Baseline clinical and demographic characteristics in CLL patients

Demographic characteristics (gender, age BMI) and disease characteristics (age at diagnosis, previous treatment, staging, prognosis criteria, constitutive symptoms)

Time frame: First interim analysis (year1) and second interim analysis (year2)

Effectiveness of acalabrutinib

Real World Progression Free Survival Overall Survival Time to next treatment or Death